Community Practice Connections™: Expert Perspectives on the Evolving Treatment Paradigm in Heart Failure Management
Released On
December 23, 2022
Expires On
December 23, 2023
Media Type
Internet
Completion Time
60 minutes
Specialty
Cardiology, Endocrinology
Topic(s)
Diabetes
Scroll to the Bottom of this Information to Begin this Course
This activity is provided by Physicians’ Education Resource®, LLC.
This activity is supported by an educational grants from Boehringer Ingelheim Pharmaceuticals, Inc, and Eli Lilly and Company Alliance.
Credit Available
- Physicians — maximum of 1.0 AMA PRA Category 1 Credits™
- Nurses — 1.0 Contact Hours
All other healthcare professionals completing this course will be issued a statement of participation.
Target Audience
This educational activity is directed toward cardiologists, internists, primary care physicians, endocrinologists, nephrologists, hospitalists, physician assistants, nurse practitioners, pharmacists, and certified diabetes educators.
Program Overview
Heart failure (HF) remains a leading cause of morbidity and mortality. Despite the fact that guideline-directed medical therapy (GDMT) has been shown to improve HF survival, GDMT optimization in clinical practice remains poor. Recent guideline updates have added an additional class of pharmacologic therapies as new tools for managing this disease. Continuing medical education is important for keeping clinicians who treat patients with HF informed of new standards of care and state-of-the-art management practices.
This Community Practice Connections™ program provides an in-depth review of some of the key highlights from a hybrid satellite symposium held adjunct to the Heart Failure Society of America Annual Scientific Meeting 2022, convened in October. This unique and engaging multimedia activity is ideal for the community-based clinician and focuses on the practical aspects of managing patients with HF, putting recent clinical trial data into clinical context. The program is designed for those who did not attend the live meeting and to help reinforce learnings for those who did.
Learning Objectives
- Upon completion of this activity, participants should be better able to:
-
- Identify diagnostic strategies for HF
- Apply evidence-based guidelines for treatment selection for HF and its comorbidities
- Outline the mechanisms of action of emerging therapies for HF
- Differentiate clinical trial evidence for emerging therapies to manage HF
Faculty
Andrew Sauer, MD
Program Chair
Associate Professor
Saint Luke’s Health System
Kansas City, MO
Justin Ezekowitz, MBBCh, MSc
Co-Director
Canadian VIGOUR Centre
Professor, Division of Cardiology
Director, Cardiovascular Research
University of Alberta
Mazankowski Alberta Heart Institute
Edmonton, AB
Aferdita Spahillari, MD, MPH
Assistant Professor
Massachusetts General Hospital
Boston, MA
Ashley Tringale, MSN, AGACNP-BC
Massachusetts General Hospital
Boston, MA
Accreditation/Credit Designation
In support of improving patient care, the Heart Failure Society of America is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The Heart Failure Society of America designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Learners should claim only the credit commensurate with the extent of their participation in the activity.
This educational activity is approved for nursing continuing professional development (NCPD) units by the Heart Failure Society of America. This activity is approved for a maximum 1.0 contact hours. Learners should claim only the credit commensurate with the extent of their participation in the activity.
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.
- Andrew Sauer, MD
-
- Consultant: Abbott; Boston Scientific Corporation; Endotronix; Medtronic
- Justin Ezekowitz, MBBCh, MSc
-
- Grant/Research Support: American Regent, Inc; Amgen; Applied Therapeutics; AstraZeneca; Bayer; Cytokinetics, Inc; Merck; Novartis; Otsuka America Pharmaceutical, Inc; Pfizer; Servier Group
- Consultant: AstraZeneca; Bayer; Boehringer Ingelheim; Merck; Otsuka America Pharmaceutical, Inc.
Aferdita Spahillari, MD, MPH, has no relevant financial relationships with ineligible companies.
Ashley Tringale, MSN, AGACNP-BC, has no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Instructions for Participation and Credit
- Complete the activity (including pre- and post-activity assessments).
- Answer the evaluation questions.
- Request credit using the drop-down menu.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.